Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

NCT02909933 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of low-dose liraglutide combined with metformin versus high-dose liraglutide alone on body weight in people with polycystic ovary syndrome and obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people

Who can join Ages 18–55 · female only

Timeline Started 2015-07 · est. completion 2015-10

Where 1 site · Slovenia

What this study is testing ClinicalTrials.gov NCT02909933 ↗

Description as written by the study sponsor.

Weight reduction is the most important treatment target when polycystic ovary syndrome (PCOS) is linked to obesity. Liraglutide (LIRA) in dose of 3 mg was recently approved as an anti-obesity drug. Metformin could enhance weight lowering potential of liraglutide. We investigates short term interventions with low dose liraglutide in combination with metformin and high dose liraglutide alone influence on significant weight reduction in obese women with PCOS.

Treatments tested

liraglutide also known as Victoza Drug
metformin and liraglutide also known as Glucophage and Victoza Drug

Main thing measured	The main outcome was change in body weight.
Sponsor	University Medical Centre Ljubljana
Conditions studied	Polycystic Ovary Syndrome, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02909933 ↗